Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant

J Clin Endocrinol Metab. 2009 Feb;94(2):477-82. doi: 10.1210/jc.2008-1293. Epub 2008 Nov 11.

Abstract

Context: Preterm birth is followed by a decrease in circulatory levels of IGF-I and IGF binding protein (IGFBP)-3, proteins with important neurogenic and angiogenic properties.

Objective: Our objective was to evaluate the effects of iv administration of fresh-frozen plasma (FFP) from adult donors on circulatory levels of IGF-I and IGFBP-3 in extremely preterm infants.

Design, setting, and patients: A prospective cohort study was performed in 20 extremely preterm infants [mean (SD) gestational age 25.3 (1.3) wk] with clinical requirement of FFP during the first postnatal week. Sampling was performed before initiation of transfusion, directly after, and at 6, 12, 24, and 48 h after completed FFP transfusion.

Main outcome measures: Concentrations of IGF-I and IGFBP-3 before and after transfusion of FFP were determined.

Results: FFP with a mean (SD) volume of 11 ml/kg (3.1) was administered at a median postnatal age of 2 d (range 1-7). Mean (SD) IGF-I and IGFBP-3 concentrations in administered FFP were 130 (39) and 2840 microg/liter (615), respectively. Immediately after FFP transfusion, mean (SD) concentrations of IGF-I increased by 133% from 11 (6.4) to 25 microg/liter (9.3) (P < 0.001) and IGFBP-3 by 61% from 815 (451) to 1311 microg/liter (508) (P < 0.001). Concentrations of IGF-I and IGFBP-3 remained higher at 6 (P < 0.001, P = 0.009) and 12 h (P = 0.017, P = 0.018), respectively, as compared with concentrations before FFP transfusion. Typical half-life of administrated IGF-I was 3.4 h for a 1-kg infant.

Conclusion: Transfusion of FFP to extremely preterm infants during the first postnatal week elevates levels of IGF-I and IGFBP-3.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / analysis
  • Blood Transfusion* / methods
  • Combined Modality Therapy
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight* / blood
  • Infant, Newborn
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor Binding Proteins / analysis
  • Insulin-Like Growth Factor Binding Proteins / blood
  • Insulin-Like Growth Factor I / administration & dosage*
  • Insulin-Like Growth Factor I / analysis
  • Insulin-Like Growth Factor I / deficiency
  • Parenteral Nutrition
  • Plasma* / chemistry
  • Plasma* / physiology
  • Premature Birth / blood
  • Premature Birth / therapy*
  • Treatment Outcome

Substances

  • Blood Glucose
  • IGFBP3 protein, human
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor Binding Proteins
  • Insulin-Like Growth Factor I